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THE ROLE OF ENDOTHELIAL DYSFUNCTION 
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REFLUX DISEASE DEVELOPMENT IN PATIENTS 
WITH ISCHEMIC HEART DISEASE
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SUMMARY – Ischemic heart disease (IHD) and gastroesophageal refl ux disease (GERD) are 
among the most common diseases worldwide, which in a considerable percentage of cases occur to-
gether, thus complicating symptoms, posing problems for timely diagnosis and hindering develop-
ment of a comprehensive treatment regimen for both diseases. Research has shown that endothelial 
dysfunction is one of the major pathophysiological mechanisms in the development of IHD. Endo-
thelial dysfunction also aff ects regional perfusion of the esophagus, thus compromising esophageal 
tissue defense mechanisms. Th e aim of our study was to investigate the role of endothelial dysfunction 
in the mechanisms of GERD development in patients with IHD. For the purpose of this study, we 
collected data on serum levels of endothelin-1, nitric oxide metabolites and lipid peroxidation prod-
ucts, gastric pH, parameters of regional blood fl ow, and quality of life assessment. Study results re-
vealed that in IHD patients with concomitant GERD, endothelial dysfunction manifested by a sig-
nifi cant increase in the levels of endothelin-1 and lipid peroxidation products, with decreased levels of 
nitric oxide metabolites, regional blood fl ow and quality of life. Th ese fi ndings suggest that hypoxia of 
the esophageal mucosa, caused by endothelial dysfunction, leads to a decrease in the esophageal tissue 
resistance and to esophageal lower sphincter dysfunction, which, in turn, are the leading factors in the 
development of GERD.
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Introduction
Ischemic heart disease (IHD) continues to be one 
of the most common diseases worldwide1,2. In recent 
years, there has been an increasing trend in the inci-
dence of the disease in younger people and in clinical 
comorbidity. One of the leading places in comorbid 
pathology belongs to gastroesophageal refl ux disease 
(GERD)1,3. Research data suggest that more than one-
third of patients with coronary heart disease suff er 
from refl ux esophagitis of varying severity while more 
than 60% of non-cardiac chest pain episodes in pa-
tients with IHD are associated with GERD3,4. Th e 
concurrent presence of these diseases modifi es symp-
toms, aggravates clinical presentation and jeopardizes 
the timeliness of the correct diagnosis2,3. A number of 
factors and mechanisms contribute to the develop-
ment of such comorbidity. Shared aff erent vagal in-
nervation of the esophagus and the heart is responsible 
for similarity in clinical presentations of esophageal 
and cardiac chest pain. Vagal innervation is also the 
underlying mechanism for cardiac arrhythmia and 
ischemia being triggered by esophageal irritation with 
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acidic refl uxate, as well as esophageal spasm being trig-
gered by cardiac ischemia4,5. Several studies have 
shown that development of GERD symptoms is 
caused by the use of aspirin, calcium channel blockers 
and nitrates, medications commonly used for IHD6,7. 
Nitrates decrease lower esophageal sphincter pressure, 
calcium channel blockers aff ect esophageal motility 
slowing peristalsis, and aspirin is an esophageal and 
gastric mucosa irritant. All these drug-related mecha-
nisms contribute to the development of GERD in pa-
tients with IHD. Substantial research data suggest 
that endothelial dysfunction is the leading mechanism 
in the pathogenesis of IHD. With regard to the esoph-
agus, endothelial dysfunction aff ects regional blood 
circulation causing tissue hypoxia, thus decreasing 
esophageal tissue resistance and its ability to withstand 
acidic refl uxate8-11.
Based on this, the purpose of the present study was 
to investigate the role of endothelial dysfunction in the 
mechanisms of development of GERD in patients 
with IHD.
Subjects and Methods
Th e present study was conducted in a total of 105 
adult subjects divided into three groups. Group 1 in-
cluded 45 adults (30 women and 15 men) aged 35 to 
45 years with angina pectoris I-II functional class co-
morbid with non-erosive form of GERD. Th e diagno-
sis of IHD was based on ICD-10 classifi cation, while 
the diagnosis of GERD was based on ICD-10 and the 
Montreal Consensus 2006 recommendations. Patients 
with other comorbidities such as obesity, insulin resis-
tance, diabetes, chronic obstructive pulmonary disease, 
and coronary syndrome were not included in the study 
group. Group 2 consisted of 40 adults (26 women and 
14 men) aged 33 to 44 years with non-erosive form of 
GERD without comorbidity. Control group consisted 
of 20 healthy individuals of both sexes aged 33 to 44 
years. Th e study was conducted at clinical sites of the 
Department of Th erapy, Rheumatology and Clinical 
Pharmacology, Kharkiv Medical Academy of Post-
graduate Education. Th e study was approved by the 
institutional Ethics Committee of the Kharkiv Medi-
cal Academy of Postgraduate Education and by ad-
ministrations of the clinical sites. A written informed 
consent was obtained from all study participants.
Endothelial function assessment was performed by 
measurement of serum levels of endothelin-1, nitric 
oxide (NO) metabolites and lipid peroxidation prod-
ucts. Endothelin-1 level was measured using commer-
cially available Endothelin-1 ELISA System kit, ac-
cording to the manufacturer’s protocol (Amersham 
Pharmacia Biotech, UK). Levels of stable NO metab-
olites (NO2 blood and NO2 + NO3 blood) was deter-
mined by spectrometry (Griess-Ilosvaya method). 
Quantifi cation of the lipid peroxidation products was 
performed by measuring levels of serum thiobarbituric 
acid-reactive substances (TBARS) using a commer-
cially available ELISA kit, according to the manufac-
turer’s protocol (HBO REAKOMPLEKS, Russia).
Gastric secretory function was assessed by en-
dogastric pH-metry with ML-2 unit (production of 
Ukraine).
Th e 12-lead baseline electrocardiography (ECG) 
was performed according to standard procedures on 
the UCARD-200 unit (production of Russia).
Th e state of the regional blood circulation was as-
sessed by measurement of blood fl ow velocity and ce-
liac trunk diameter. Th ese parameters were determined 
using sonography with color Doppler mapping per-
formed on an Aloka-SSD-650 ultrasound apparatus 
(production of Japan).
Patient quality of life was assessed by using the 
SF-36 questionnaire.
Statistical data processing was carried out by the 
methods of variation and parametric statistics for bio-
medical research using Excel for Windows and Statis-
tica 6.0 software.
Results and Discussion
Th e mean values of endothelin-1 levels were as 
 follows: 8.3±0.57 pmol/L in group 1 patients (IHD + 
GERD) and 4.1±0.23 pmol/L in group 2 patients 
(GERD), indicating signifi cant increase in compari-
son with normal values of 1.92±0.23 pmol/L. Th e lev-
els of endothelin-1 in control group were within the 
normal limits.
Th e mean levels of stable NO metabolites were 
as follows: group 1, NO2 1.33±0.5 μmol/L and 
NO2+NO3 19.78±2.77 μmol/L; group 2, NO2 
1.9±0.20 μmol/L and NO3+NO2 25.41±9.85 μmol 
/L. Th e results were indicative of signifi cant decrease 
in the levels of stable NO metabolites when compared 
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with normal values (NO2 2.8±0.22 μmol/L and 
NO2+NO3 31.50±3.05 μmol/L) and those recorded 
in control group.
Th ere were apparent diff erences in the results be-
tween the study groups. Group 1 patients had a statis-
tically signifi cant (p<0.001) increase in endothelin-1 
levels and decrease in the levels of stable NO metabo-
lites as compared with group 2 and control group. 
Group 2 patients showed a statistically signifi cant in-
crease in the levels of endothelin-1 and decrease in the 
levels of stable NO metabolites compared with control 
group, but deviation from the normal values was sig-
nifi cantly lower than in group 1 patients. Furthermore, 
in group 1, deviation from the normal levels of endo-
thelin-1 (increase) was more pronounced than changes 
in the levels of NO metabolites (decrease), while de-
viations from the normal levels of those biomarkers in 
group 2 patients were comparable.
Th e mean level of TBARS was 11.81±0.62 μmol 
/L in group 1 and 15.25±0.74 μmol/L in group 2, in-
dicating signifi cant increase as compared with normal 
levels of 4.5±0.35 μmol/L. On group comparison, 
group 2 patients had signifi cantly higher levels of lipid 
peroxidation products than both group 1 and control 
group.
Assessment of the regional blood circulation re-
vealed a statistically signifi cant reduction in the celiac 
trunk diameter and decrease in blood fl ow velocity in 
the celiac trunk in both groups 1 and 2 as compared 
with normal values of 0.99±0.14 cm for celiac trunk 
diameter and 14.4±0.9 cm/s for blood fl ow velocity. 
Th e mean values of celiac trunk diameter were 0.7±0.1 
cm in group 1 and 0.88±0.12 cm in group 2. Th e mean 
blood fl ow velocity measured 7.8±0.5 cm/s in group 1 
and 10.3±0.6 cm/s in group 2. In group 1 patients, de-
crease in the celiac trunk diameter prevailed over de-
crease in blood fl ow velocity in its signifi cance. Group 
comparison showed the decrease in the values of celiac 
trunk diameter and blood fl ow velocity in group 2 pa-
tients to be apparent in comparison with control group, 
but less signifi cant than in group 1 patients.
Gastric pH was measured in the body of the stom-
ach, with pH 1.7±0.2 being considered a normal value. 
Th e mean value of gastric pH was 1.3±0.1 in group 1 
and 1.1±0.1 in group 2. Such a decrease in pH values 
indicated increase in gastric acidity, which was signifi -
cantly greater in group 2 patients in comparison with 
both the control group and group 1 patients.
Th e study revealed a signifi cant decrease in the 
quality of life indicators in all main domains of the 
SF-36 scale for both patient groups as compared with 
the control group (p<0.001). Moreover, in patients 
with IHD and concomitant GERD, severe decline 
was recorded in the general health and social function-
ing scales, which amounted to 42.3±4.5 points and 
51.2±4.4 points, respectively (normal, 77.8±5.1 points 
and 85.3±4.6 points, respectively). At the same time, in 
patients with GERD without comorbidity, the scores 
were 55.9±3.7 and 68.2±3.3 points, respectively. Th us, 
according to the results, the indicators were signifi -
cantly higher in group 2 than in control group 
(p<0.001), but signifi cantly lower than in group 1. At 
the same time, the indicators of pain intensity scales, 
role and physical functioning were signifi cantly higher 
in group 2, with the mean values of 35.4±3.7 and 
33.2±2.8 points, respectively (normal, 75.7±4.2; 
73.8±3.2 points) as compared with control group and 
group 1 (48.4±4.5; 49.7±3.8 points).
In both patient groups, there was strong correlation 
(group 1, r=0.76; group 2, r=0.70) between the quality 
of life scores and study variables, i.e. levels of endothe-
lin-1, NO metabolites, lipid peroxidation products, 
parameters of regional blood fl ow, and gastric pH. 
Study results suggest that endothelial dysfunction 
plays one of the leading roles in the development of 
GERD in IHD patients. Endothelial dysfunction is 
evidenced by a signifi cant increase in the levels of en-
dothelin-1 and decrease in the levels of NO metabo-
lites and parameters of regional blood fl ow in celiac 
trunk, which reduces esophageal tissue resistance and 
results in the lower esophageal sphincter dysfunction. 
In GERD patients without concomitant pathology, 
stress evidenced by increase in the quality of life indi-
cators (intensity of pain, role and physical functioning) 
triggers an increased production of hydrochloric acid 
in the stomach and elevation of endothelin-1 levels. 
Th is, in turn, leads to a decrease in regional blood fl ow 
and tissue hypoxia, resulting in higher rates of lipid 
peroxidation products, and reduced esophageal tone 
and motility, and helps maintain the increased produc-
tion of hydrochloric acid. It may be extrapolated that 
endothelial dysfunction is one of the major mecha-
nisms that triggers the development of GERD in 
IHD patients. Besides, in patients with isolated 
GERD, endothelial dysfunction can develop as a sec-
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ondary pathology, aggravating the clinical course of 
the disease. Th e study fi ndings suggest that in IHD 
patients with concomitant GERD, the anti-refl ux bar-
rier dysfunction at the esophagogastric junction occurs 
due to reduced esophageal tissue defense mechanisms 
resulting from perfusion-related tissue hypoxia, where-
as in GERD patients without comorbidity, anti-refl ux 
barrier dysfunction is induced by the increased corro-
sive properties of refl uxate. Study results pointed to the 
need for a diff erentiated approach to treatment based 
on the specifi c role endothelial dysfunction plays in 
the pathophysiology of both diseases.
Conclusions
1. Patients with IHD and concomitant GERD 
have a signifi cant decrease in the quality of life 
parameters on all scales compared with control 
group, and in the general health and social 
functioning indicators, signifi cantly higher than 
in GERD patients without comorbidity. In pa-
tients with isolated GERD, the study demon-
strated a signifi cant increase in pain, physical 
functioning and role-playing indicators com-
pared with normal values and group 1 patients.
2. Patients with IHD and concomitant GERD 
showed a statistically signifi cant increase in en-
dothelin-1 levels and decrease in the levels 
of stable NO metabolites as compared with 
GERD patients without comorbidity and con-
trol group.
3. Patients with GERD without comorbidity had 
distinct reduction in the values of celiac trunk 
diameter and blood fl ow velocity in comparison 
with control group, but less signifi cant than in 
IHD patients with concomitant GERD.
4. Increase in the levels of lipid peroxidation prod-
ucts and increased gastric juice acidity in IHD 
patients with concomitant GERD was appar-
ent as compared with control group, but less 
signifi cant than in GERD patients without co-
morbidity.
5. Th e fi ndings suggest that endothelial dysfunc-
tion in IHD patients with concomitant GERD 
aff ects esophageal tissue defense mechanisms 
precipitating anti-refl ux barrier dysfunction at 
the esophagogastric junction, while in GERD 
patients without comorbidity it potentiates cor-
rosive properties of refl uxate.
Results of the study will contribute to more exten-
sive detection of endothelial dysfunction in patients 
with IHD accompanied by GERD. In addition, these 
results will be used to develop methods for preventing 
development of GERD in patients with IHD.
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Sažetak
ULOGA ENDOTELNE DISFUNKCIJE U MEHANIZMU NASTANKA 
GASTROEZOFAGUSNE REFLUKSNE BOLESTI KOD BOLESNIKA S KORONARNOM BOLESTI SRCA
A. Oparin i A. Vnukova
Danas su koronarna bolest srca (KBS) i gastroezofagusna refl uksna bolest (GERD) među najčešćim bolestima u svijetu 
koje se u značajnom postotku slučajeva javljaju komorbidno pri čemu znatno otežavaju kliničku sliku i razvoj sveobuhvatne 
sheme terapije za obje bolesti. S obzirom na to da poremećaj funkcije endotela igra važnu ulogu u nastanku KBS, kao i u 
održavanju rezistentnosti tkiva jednjaka, cilj našega istraživanja bio je procijeniti ulogu endotelne disfunkcije u mehanizmu 
nastanka GERB kod bolesnika s KBS. Polazeći od postavljenog cilja mjerili smo serumske razine endotelina-1, metabolite 
dušikova oksida i produkata peroksidacije lipida, želučani pH, parametre regionalnog protoka krvi te kvalitetu života bole-
snika. Rezultati su pokazali da se endotelna disfunkcija u bolesnika s IHD i GERD očituje povišenim razinama endotelina-1 
i produkata peroksidacije lipida, uz snižene razine metabolita dušikova oksida, regionalnog protoka krvi i kvalitete života. Ovi 
nalazi ukazuju na to da hipoksija ezofagusne sluznice uzrokovana endotelnom disfunkcijom dovodi do smanjenja otpornosti 
ezofagusnog tkiva i disfunkcije donjeg ezofagusnog sfi nktera, a to su vodeći čimbenici razvoja GERD.
Ključne riječi: Miokard, ishemija; Gastroezofagusni refl uks; Endotelin-1; Dušični oksid; Lipidna peroksidacija; Regionalni 
optok krvi; Kvaliteta života; Hipoksija; Ezofagusni sfi nkter, donji
